National Cancer Center

Toray Industries, Inc.

Carna Biosciences, Inc.

Transgenic Inc.

Japan Health Sciences Foundation

President, National Cancer Center

Sysmex Corporation

Mychunter Therapeutics, Inc.

Tesshi Yamada

Masayuki Yoshida

Kazufumi Honda

Masaaki Sawa

Yoshiaki Osaka

Giman Jung

Michimoto Kobayashi

Yoshiyuki Sasajima

Setsuo Hirohashi

Mitsuaki Sanada

Hideki Moriyama

Yuko Uno

Miki Shitashige

Masaya Ono

Aiko Takayama

Shigeki Kashimoto

Koichi Yokota

Shingo Shinagawa

Yusuke Kawase

Hiroshi Nose

Mari Masuda

Tomoyo Hashiguchi

Kazunari Ito

Yoshimi Tokashiki

Tomoaki Miyamoto

Yosuke Makuuchi

Teppei Sugano

The purpose of the present invention is to provide a simple and highly accurate method for detecting pancreatic exocrine dysfunction with minimal invasiveness to a subject. The method comprising in vitro measurement of two APOA2 protein variants, mutants thereof and/or fragments thereof in a body fluid sample derived from the subject and detection of the presence or absence of pancreatic exocrine dysfunction on the basis of the measured amounts, and a detection kit for pancreatic exocrine dysfunction including antibodies that can specifically bind to said proteins are provided.

Method and kit for the detection of pancreatic dysfunction

The present invention provides a method for detecting biliary tract cancer by measuring the amounts of APOA2 protein variants in a test sample with anti-APOA2 antibodies, the anti-APOA2 antibodies for use in the above method and a detection kit for biliary tract cancer including the above antibodies.

Method and kit for the detection of biliary tract cancer

The present invention provides a quinazoline derivative represented by the following formula (I): wherein Rand Rrepresent a hydrogen atom, a halogen atom, or a lower alkyl group optionally having a substituent; Z represents a cycloalkyl group having a substituent or a cycloalkenyl group having a substituent; and Q represents a bicyclic heteroaryl group optionally having a substituent, or a pharmaceutically acceptable salt thereof. Since the compound has an inhibitory effect on the Wnt/&#x3b2;-catenin signaling pathway and exhibits an antitumor effect, it is useful as a medicine.

Quinazoline derivative

An antibody against mutant &#x3b1;-actinin-4 having an amino acid sequence with at least one amino acid residue substitution in the region between position 245 and 263 in the amino acid sequence of &#x3b1;-actinin-4, wherein the antibody recognizes all or a part of the substituted amino acid residue(s) in the region.

Antibody against mutant &#x3b1;-actinin-4

The present invention relates to novel bicyclic thiazole compounds that inhibit Traf2- and Nck-interacting kinase (TNIK), and as such are useful as TNIK inhibitors administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. The bicyclic thiazole compounds are showed by a next formula (I). (wherein R, R, Rand Q are as defined in the specification), or a pharmaceutically acceptable salt thereof. 

Bicyclic thiazole compounds

The present invention provides an antibody, which reacts with a FGA or FGA partial peptide in which a part of prolines in the molecule thereof are hydroxylated, and which does not react with an unmodified FGA or FGA partial peptide.

High specificity monoclonal antibody against a protein or a polypeptide having oxidative modification

The screening method for an anticancer drug comprises selecting a compound which blocks the kinase activity of TNIK, or blocks the combination of TNIK with &#x3b2;-catenin/TC4 transcription complex.

Screening method for anticancer drug

A novel protein and a fragment thereof useful as a tumor marker of pancreatic cancer are disclosed. This protein or a fragment thereof is a modified &#x3b1;-fibrinogen protein containing an oxidized amino acid residue(s) or a fragment thereof containing said oxidized amino acid residue(s). The oxidized amino acid residue(s) is one or more amino acid residues selected from the group consisting of (a) a proline residue corresponding to the proline residue at the position of 530 in SEQ ID NO: 2, and (b) a proline residue corresponding to the proline residue at the position of 565 in SEQ ID NO: 2.

Tumor marker for pancreatic cancer

Growing community of inventors

Tokyo, Japan

Tesshi Yamada